Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions

Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions piration, Lipitor was actually cheaper during 2011 than its generic equivalent. Payments to Physicians, Prescribing Rates, Physicians might choose atorvastatin over other statins, and More Appropriate Conclusions as studies have shown it may be superior in the settings of myo- To the Editor In a study in a recent issue of JAMA Internal cardial infarction and cerebrovascular events and for overall Medicine, Yeh et al draw a broad conclusion that there is a posi- 3-5 1 lipid reduction. Since Yeh et al used a claims database, they tive linear relationship between pharmaceutical industry pay- had no information on why clinicians chose a particular statin ments to physicians and higher rates of prescribing brand name and not another. The frequent use of atorvastatin in 2011 could statins. The authors, however, acknowledge that there is no such be based on the studies indicating increased efficacy over other relationship over the range of $0 to $2000 per physician during available statins. the study period. The article does not include the number of phy- 1 It may not have been possible for Yeh et al to answer the sicians in this group, but because the median payment for the key question they set http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions

JAMA Internal Medicine , Volume 176 (10) – Oct 1, 2016

Loading next page...
 
/lp/american-medical-association/payments-to-physicians-prescribing-rates-and-more-appropriate-oyzXDGjgKI

References (9)

Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2016.5796
pmid
27695839
Publisher site
See Article on Publisher Site

Abstract

piration, Lipitor was actually cheaper during 2011 than its generic equivalent. Payments to Physicians, Prescribing Rates, Physicians might choose atorvastatin over other statins, and More Appropriate Conclusions as studies have shown it may be superior in the settings of myo- To the Editor In a study in a recent issue of JAMA Internal cardial infarction and cerebrovascular events and for overall Medicine, Yeh et al draw a broad conclusion that there is a posi- 3-5 1 lipid reduction. Since Yeh et al used a claims database, they tive linear relationship between pharmaceutical industry pay- had no information on why clinicians chose a particular statin ments to physicians and higher rates of prescribing brand name and not another. The frequent use of atorvastatin in 2011 could statins. The authors, however, acknowledge that there is no such be based on the studies indicating increased efficacy over other relationship over the range of $0 to $2000 per physician during available statins. the study period. The article does not include the number of phy- 1 It may not have been possible for Yeh et al to answer the sicians in this group, but because the median payment for the key question they set

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Oct 1, 2016

There are no references for this article.